Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer

Pharmacology and Therapeutics

Volumn 179, Issue , 2017, Pages 127-141

  Rose, April A N ^a,b   Biondini, Marco ^a,b   Curiel, Rafael ^c   Siegel, Peter M ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Celldex Therapeutics Inc   (United Kingdom)

Author keywords

Antibody drug conjugate; Cancer therapy; Glembatumumab vedotin; GPNMB

Indexed keywords

BIOLOGICAL MARKER; GLEMBATUMUMAB VEDOTIN; GLYCOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; ANTIBODY CONJUGATE; GPNMB PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY;

ALOPECIA; ANOREXIA; BRAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER THERAPY; CONSTIPATION; DIARRHEA; DRUG INDICATION; DRUG TARGETING; DYSGEUSIA; FATIGUE; GLYCOPROTEIN NMB GENE; HUMAN; IMMUNE SYSTEM; LOSS OF APPETITE; MALIGNANT NEOPLASM; MARKER GENE; MELANOMA; METASTASIS; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PRURITUS; RASH; REVIEW; SKIN; ANIMAL; CHEMISTRY; METABOLISM; NEOPLASM;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOMARKERS; HUMANS; IMMUNOCONJUGATES; MEMBRANE GLYCOPROTEINS; NEOPLASMS;

EID: 85019943577     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2017.05.010     Document Type: Review

References (130)

1. Abdelmagid, S.M., Barbe, M.F., Arango-Hisijara, I., Owen, T.A., Popoff, S.N., Safadi, F.F., Osteoactivin acts as downstream mediator of BMP-2 effects on osteoblast function. Journal of Cellular Physiology 210 (2007), 26–37.
2. Abdelmagid, S.M., Belcher, J.Y., Moussa, F.M., Lababidi, S.L., Sondag, G.R., Novak, K.M., Safadi, F.F., Mutation in osteoactivin decreases bone formation in vivo and osteoblast differentiation in vitro. The American Journal of Pathology 184 (2014), 697–713.
3. Ahn, J.H., Lee, Y., Jeon, C., Lee, S.J., Lee, B.H., Choi, K.D., Bae, Y.S., Identification of the genes differentially expressed in human dendritic cell subsets by cDNA subtraction and microarray analysis. Blood 100 (2002), 1742–1754.
4. Alam, M.S., Getz, M., Safeukui, I., Yi, S., Tamez, P., Shin, J., Haldar, K., Genomic expression analyses reveal lysosomal, innate immunity proteins, as disease correlates in murine models of a lysosomal storage disorder. PLoS One, 7, 2012, e48273.
5. Amaral, T., Sinnberg, T., Meier, F., Krepler, C., Levesque, M., Niessner, H., Garbe, C., MAPK pathway in melanoma part II—Secondary and adaptive resistance mechanisms to BRAF inhibition. European Journal of Cancer 73 (2017), 93–101.
6. Ansell, S.M., Northfelt, D.W., Flinn, I., Burris, H.A., Dinner, S.N., Villalobos, V.M., Davis, T.A., Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies. Journal of Clinical Oncology, 32, 2014, 3024.
7. Arosarena, O.A., Dela Cadena, R.A., Denny, M.F., Bryant, E., Barr, E.W., Thorpe, R., Safadi, F.F., Osteoactivin promotes migration of oral squamous cell carcinomas. Journal of Cellular Physiology 231 (2016), 1761–1770.
8. Bandari, P.S., Qian, J., Yehia, G., Joshi, D.D., Maloof, P.B., Potian, J., Rameshwar, P., Hematopoietic growth factor inducible neurokinin-1 type: A transmembrane protein that is similar to neurokinin 1 interacts with substance P. Regulatory Peptides 111 (2003), 169–178.
9. Basrur, V., Yang, F., Kushimoto, T., Higashimoto, Y., Yasumoto, K., Valencia, J., Appella, E., Proteomic analysis of early melanosomes: Identification of novel melanosomal proteins. Journal of Proteome Research 2 (2003), 69–79.
10. Bendell, J., Saleh, M., Rose, A.A., Siegel, P.M., Hart, L., Sirpal, S., Vahdat, L., Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer. Journal of Clinical Oncology 32 (2014), 3619–3625.
11. Bhaskaran, M., Xi, D., Wang, Y., Huang, C., Narasaraju, T., Shu, W., Liu, L., Identification of microRNAs changed in the neonatal lungs in response to hyperoxia exposure. Physiological Genomics 44 (2012), 970–980.
12. Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F.L., Carbonnel, F., Robert, C., Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews. Clinical Oncology 13 (2016), 473–486.
13. Brozyna, A.A., Jozwicki, W., Carlson, J.A., Slominski, A.T., Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma. Human Pathology 44 (2013), 2071–2074.
14. Brozyna, A.A., Jozwicki, W., Roszkowski, K., Filipiak, J., Slominski, A.T., Melanin content in melanoma metastases affects the outcome of radiotherapy. Oncotarget, 2016, 17844–17853.
15. Cancer Genome Atlas Network, Electronic address i m o, Cancer Genome Atlas N, Genomic classification of cutaneous melanoma. Cell 161 (2015), 1681–1696.
16. Chi, A., Valencia, J.C., Hu, Z.Z., Watabe, H., Yamaguchi, H., Mangini, N.J., Hunt, D.F., Proteomic and bioinformatic characterization of the biogenesis and function of melanosomes. Journal of Proteome Research 5 (2006), 3135–3144.
17. Chung, J.S., Bonkobara, M., Tomihari, M., Cruz, P.D. Jr., Ariizumi, K., The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses. European Journal of Immunology 39 (2009), 965–974.
18. Chung, J.S., Dougherty, I., Cruz, P.D. Jr., Ariizumi, K., Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation. Journal of Immunology 179 (2007), 5778–5784.
19. Chung, J.S., Sato, K., Dougherty, I.I., Cruz, P.D. Jr., Ariizumi, K., DC-HIL is a negative regulator of T lymphocyte activation. Blood 109 (2007), 4320–4327.
20. Chung, J.S., Shiue, L.H., Duvic, M., Pandya, A., Cruz, P.D. Jr., Ariizumi, K., Sezary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface. Blood 117 (2011), 3382–3390.
21. Chung, J.S., Tamura, K., Akiyoshi, H., Cruz, P.D. Jr., Ariizumi, K., The DC-HIL/syndecan-4 pathway regulates autoimmune responses through myeloid-derived suppressor cells. Journal of Immunology 192 (2014), 2576–2584.
22. Chung, J.S., Tamura, K., Cruz, P.D. Jr., Ariizumi, K., DC-HIL-expressing myelomonocytic cells are critical promoters of melanoma growth. The Journal of Investigative Dermatology 134 (2014), 2784–2794.
23. Chung, J.S., Tomihari, M., Tamura, K., Kojima, T., Cruz, P.D. Jr., Ariizumi, K., The DC-HIL ligand syndecan-4 is a negative regulator of T-cell allo-reactivity responsible for graft-versus-host disease. Immunology 138 (2013), 173–182.
24. Chung, J.S., Yudate, T., Tomihari, M., Akiyoshi, H., Cruz, P.D. Jr., Ariizumi, K., Binding of DC-HIL to dermatophytic fungi induces tyrosine phosphorylation and potentiates antigen presenting cell function. Journal of Immunology 183 (2009), 5190–5198.
25. Dror, S., Sander, L., Schwartz, H., Sheinboim, D., Barzilai, A., Dishon, Y., Levy, C., Melanoma miRNA trafficking controls tumour primary niche formation. Nature Cell Biology 18 (2016), 1006–1017.
26. Fiorentini, C., Bodei, S., Bedussi, F., Fragni, M., Bonini, S.A., Simeone, C., Sigala, S., GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity. Experimental Cell Research 323 (2014), 100–111.
27. Flaherty, K.T., Infante, J.R., Daud, A., Gonzalez, R., Kefford, R.F., Sosman, J., Weber, J., Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. The New England Journal of Medicine 367 (2012), 1694–1703.
28. Frara, N., Abdelmagid, S.M., Sondag, G.R., Moussa, F.M., Yingling, V.R., Owen, T.A., Safadi, F.F., Transgenic expression of osteoactivin/gpnmb enhances bone formation in vivo and osteoprogenitor differentiation ex vivo. Journal of Cellular Physiology 231 (2016), 72–83.
29. Frederick, D.T., Piris, A., Cogdill, A.P., Cooper, Z.A., Lezcano, C., Ferrone, C.R., Wargo, J.A., BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clinical Cancer Research 19 (2013), 1225–1231.
30. Furochi, H., Tamura, S., Mameoka, M., Yamada, C., Ogawa, T., Hirasaka, K., Nikawa, T., Osteoactivin fragments produced by ectodomain shedding induce MMP-3 expression via ERK pathway in mouse NIH-3T3 fibroblasts. FEBS Letters 581 (2007), 5743–5750.
31. Gabriel, T.L., Tol, M.J., Ottenhof, R., van Roomen, C., Aten, J., Claessen, N., van Eijk, M., Lysosomal stress in obese adipose tissue macrophages contributes to MITF-dependent Gpnmb induction. Diabetes 63 (2014), 3310–3323.
32. Gibney, G.T., Weiner, L.M., Atkins, M.B., Predictive biomarkers for checkpoint inhibitor-based immunotherapy. The Lancet Oncology 17 (2016), e542–e551.
33. Gutknecht, M., Geiger, J., Joas, S., Dorfel, D., Salih, H.R., Muller, M.R., Rittig, S.M., The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells. Cell Communication and Signaling: CCS, 13, 2015, 19.
34. Halim, A., Bagley, R.G., Keler, T., Abstract 5032: Glycoprotein NMB (gpNMB) overexpression is prevalent in human cancers: Pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcoma. Cancer Research, 76, 2016, 5032.
35. Hemesath, T.J., Steingrimsson, E., McGill, G., Hansen, M.J., Vaught, J., Hodgkinson, C.A., Fisher, D.E., Microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes & Development 8 (1994), 2770–2780.
36. Hoashi, T., Sato, S., Yamaguchi, Y., Passeron, T., Tamaki, K., Hearing, V.J., Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein. The FASEB Journal 24 (2010), 1616–1629.
37. Hong, S.B., Oh, H., Valera, V.A., Baba, M., Schmidt, L.S., Linehan, W.M., Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization. PLoS One, 5, 2010, e15793.
38. Huang, J.J., Ma, W.J., Yokoyama, S., Expression and immunolocalization of Gpnmb, a glioma-associated glycoprotein, in normal and inflamed central nervous systems of adult rats. Brain and Behavior: A Cognitive Neuroscience Perspective 2 (2012), 85–96.
39. Huynh, K.K., Eskelinen, E.L., Scott, C.C., Malevanets, A., Saftig, P., Grinstein, S., LAMP proteins are required for fusion of lysosomes with phagosomes. The EMBO Journal 26 (2007), 313–324.
40. Infante, J.R., Burris, H.A., Ansell, S.M., Nemunaitis, J.J., Weiss, G.R., Villalobos, V.M., Bullock, T., Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pts) with solid tumors. Journal of Clinical Oncology, 32, 2014, 3027.
41. Johannessen, C.M., Johnson, L.A., Piccioni, F., Townes, A., Frederick, D.T., Donahue, M.K., Garraway, L.A., A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504 (2013), 138–142.
42. Kolb, E.A., Gorlick, R., Billups, C.A., Hawthorne, T., Kurmasheva, R.T., Houghton, P.J., Smith, M.A., Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatric Blood & Cancer 61 (2014), 1816–1821.
43. Kramer, G., Wegdam, W., Donker-Koopman, W., Ottenhoff, R., Gaspar, P., Verhoek, M., van Eijk, M., Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 Gaucher disease patients and mouse models. FEBS Open Bio 6 (2016), 902–913.
44. Kuan, C.T., Wakiya, K., Dowell, J.M., Herndon, J.E. II, Reardon, D.A., Graner, M.W., Bigner, D.D., Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clinical Cancer Research 12 (2006), 1970–1982.
45. Lampropoulou, A., Ruhrberg, C., Neuropilin regulation of angiogenesis. Biochemical Society Transactions 42 (2014), 1623–1628.
46. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Wolchok, J.D., Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. The New England Journal of Medicine 373 (2015), 23–34.
47. Le Borgne, R., Planque, N., Martin, P., Dewitte, F., Saule, S., Hoflack, B., The AP-3-dependent targeting of the melanosomal glycoprotein QNR-71 requires a di-leucine-based sorting signal. Journal of Cell Science 114 (2001), 2831–2841.
48. Levy, C., Khaled, M., Fisher, D.E., MITF: Master regulator of melanocyte development and melanoma oncogene. Trends in Molecular Medicine 12 (2006), 406–414.
49. Li, B., Castano, A.P., Hudson, T.E., Nowlin, B.T., Lin, S.L., Bonventre, J.V., Duffield, J.S., The melanoma-associated transmembrane glycoprotein Gpnmb controls trafficking of cellular debris for degradation and is essential for tissue repair. The FASEB Journal 24 (2010), 4767–4781.
50. Li, Y.N., Zhang, L., Li, X.L., Cui, D.J., Zheng, H.D., Yang, S.Y., Yang, W.L., Glycoprotein nonmetastatic B as a prognostic indicator in small cell lung cancer. APMIS 122 (2014), 140–146.
51. Lin, A., Li, C., Xing, Z., Hu, Q., Liang, K., Han, L., Yang, L., The LINK-A lncRNA activates normoxic HIF1alpha signalling in triple-negative breast cancer. Nature Cell Biology 18 (2016), 213–224.
52. Loftus, S.K., Antonellis, A., Matera, I., Renaud, G., Baxter, L.L., Reid, D., Pavan, W.J., Gpnmb is a melanoblast-expressed, MITF-dependent gene. Pigment Cell & Melanoma Research 22 (2009), 99–110.
53. Loging, W.T., Lal, A., Siu, I.M., Loney, T.L., Wikstrand, C.J., Marra, M.A., Riggins, G.J., Identifying potential tumor markers and antigens by database mining and rapid expression screening. Genome Research 10 (2000), 1393–1402.
54. Long, G.V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Flaherty, K., Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386 (2015), 444–451.
55. Long, G.V., Weber, J.S., Infante, J.R., Kim, K.B., Daud, A., Gonzalez, R., Flaherty, K.T., Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. Journal of Clinical Oncology 34 (2016), 871–878.
56. Maric, G., Annis, M.G., Dong, Z., Rose, A.A., Ng, S., Perkins, D., Siegel, P.M., GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin alphabeta for efficient breast cancer metastasis. Oncogene 34 (2015), 5494–5504.
57. Maric, G., Rose, A.A., Annis, M.G., Siegel, P.M., Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. OncoTargets and Therapy 6 (2013), 839–852.
58. Marin-Esteban, V., Charron, D., Gelin, C., Mooney, N., Chemotherapeutic agents targeting the tubulin cytoskeleton modify LPS-induced cytokine secretion by dendritic cells and increase antigen presentation. Journal of Immunotherapy 33 (2010), 364–370.
59. Marques, A.R., Gabriel, T.L., Aten, J., van Roomen, C.P., Ottenhoff, R., Claessen, N., van Eijk, M., Gpnmb is a potential marker for the visceral pathology in Niemann-Pick type C disease. PLoS One, 11, 2016, e0147208.
60. Metz, R.L., Yehia, G., Fernandes, H., Donnelly, R.J., Rameshwar, P., Cloning and characterization of the 5′ flanking region of the HGFIN gene indicate a cooperative role among p53 and cytokine-mediated transcription factors: Relevance to cell cycle regulation. Cell Cycle 4 (2005), 315–322.
61. Mi Hwang, S., Hyun Kang, J., Kyum Kim, B., Gi Uhm, T., Jung Kim, H., Lee, H.H., Yup Chung, I., GPNMB promotes proliferation of developing eosinophils. Journal of Biochemistry, 2017, 10.1093/jb/mvx002 Jan 18. pii: mvx002. (Epub ahead of print).
62. Mizumoto, N., Tanaka, H., Matsushima, H., Vishwanath, M., Takashima, A., Colchicine promotes antigen cross-presentation by murine dendritic cells. The Journal of Investigative Dermatology 127 (2007), 1543–1546.
63. Moskowitz, C.H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M.H., AETHERA Study Group, Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385 (2015), 1853–1862.
64. Moussa, F.M., Hisijara, I.A., Sondag, G.R., Scott, E.M., Frara, N., Abdelmagid, S.M., Safadi, F.F., Osteoactivin promotes osteoblast adhesion through HSPG and alphavbeta1 integrin. Journal of Cellular Biochemistry 115 (2014), 1243–1253.
65. Mullard, A., Maturing antibody-drug conjugate pipeline hits 30. Nature Reviews. Drug Discovery 12 (2013), 329–332.
66. Muller, P., Martin, K., Theurich, S., Schreiner, J., Savic, S., Terszowski, G., Zippelius, A., Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunology Research 2 (2014), 741–755.
67. Murugesan, V., Liu, J., Yang, R., Lin, H., Lischuk, A., Pastores, G., Mistry, P.K., Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease. Blood Cells, Molecules & Diseases, 2016, 10.1016/j.bcmd.2016.12.002 Dec 13. pii: S1079-9796(16)30239-X. (Epub ahead of print).
68. Nakano, Y., Suzuki, Y., Takagi, T., Kitashoji, A., Ono, Y., Tsuruma, K., Hara, H., Glycoprotein nonmetastatic melanoma protein B (GPNMB) as a novel neuroprotective factor in cerebral ischemia-reperfusion injury. Neuroscience 277 (2014), 123–131.
69. Narasaraju, T., Shukla, D., More, S., Huang, C., Zhang, L., Xiao, X., Liu, L., Role of microRNA-150 and glycoprotein nonmetastatic melanoma protein B in angiogenesis during hyperoxia-induced neonatal lung injury. American Journal of Respiratory Cell and Molecular Biology 52 (2015), 253–261.
70. Obeid, E., Nanda, R., Fu, Y.X., Olopade, O.I., The role of tumor-associated macrophages in breast cancer progression (review). International Journal of Oncology 43 (2013), 5–12.
71. Okita, Y., Kimura, M., Xie, R., Chen, C., Shen, L.T., Kojima, Y., Kato, M., The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB. Science Signaling, 10, 2017.
72. Onaga, M., Ido, A., Hasuike, S., Uto, H., Moriuchi, A., Nagata, K., Tsubouchi, H., Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, L-amino acid-defined diet, accelerates motility of hepatoma cells. Journal of Hepatology 39 (2003), 779–785.
73. +-ATPase. Biochemical and Biophysical Research Communications 481 (2016), 7–12.
74. Ott, P.A., Hamid, O., Pavlick, A.C., Kluger, H., Kim, K.B., Boasberg, P.D., Hwu, P., Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. Journal of Clinical Oncology 32 (2014), 3659–3666.
75. Ott, P.A., P. A. C., Johnson, D.B., Hart, L.L., Infante, J.R., Luke, J.J., Hamid, O., A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma. Annals of Oncology, 27(Supplement 6), 2016 (1147 pp.).
76. Owen, T.A., Smock, S.L., Prakash, S., Pinder, L., Brees, D., Krull, D., Popoff, S.N., Identification and characterization of the genes encoding human and mouse osteoactivin. Critical Reviews in Eukaryotic Gene Expression 13 (2003), 205–220.
77. Oyewumi, M.O., Manickavasagam, D., Novak, K., Wehrung, D., Paulic, N., Moussa, F.M., Safadi, F.F., Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells. Oncotarget 7 (2016), 13932–13944.
78. Pahl, M.V., Vaziri, N.D., Yuan, J., Adler, S.G., Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease. Clinical Journal of the American Society of Nephrology 5 (2010), 56–61.
79. Patel, S.P., Kurzrock, R., PD-L1 expression as a predictive biomarker in cancer immunotherapy. Molecular Cancer Therapeutics 14 (2015), 847–856.
80. Patel-Chamberlin, M., Wang, Y., Satirapoj, B., Phillips, L.M., Nast, C.C., Dai, T., Adler, S.G., Hematopoietic growth factor inducible neurokinin-1 (Gpnmb/Osteoactivin) is a biomarker of progressive renal injury across species. Kidney International 79 (2011), 1138–1148.
81. Planque, N., Turque, N., Opdecamp, K., Bailly, M., Martin, P., Saule, S., Expression of the microphthalmia-associated basic helix-loop-helix leucine zipper transcription factor Mi in avian neuroretina cells induces a pigmented phenotype. Cell Growth & Differentiation 10 (1999), 525–536.
82. Pogenberg, V., Ogmundsdottir, M.H., Bergsteinsdottir, K., Schepsky, A., Phung, B., Deineko, V., Wilmanns, M., Restricted leucine zipper dimerization and specificity of DNA recognition of the melanocyte master regulator MITF. Genes & Development 26 (2012), 2647–2658.
83. Pollack, V.A., Alvarez, E., Tse, K.F., Torgov, M.Y., Xie, S., Shenoy, S.G., LaRochelle, W.J., Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemotherapy and Pharmacology 60 (2007), 423–435.
84. Qian, X., Mills, E., Torgov, M., LaRochelle, W.J., Jeffers, M., Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate. Molecular Oncology 2 (2008), 81–93.
85. Qin, C., Liu, Z., Yuan, Y., Zhang, X., Li, H., Zhang, C., Wang, X., Glycoprotein non-metastatic melanoma protein B as a predictive prognostic factor in clear-cell renal cell carcinoma following radical nephrectomy. Molecular Medicine Reports 9 (2014), 851–856.
86. Ramachandran, P., Pellicoro, A., Vernon, M.A., Boulter, L., Aucott, R.L., Ali, A., Iredale, J.P., Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proceedings of the National Academy of Sciences of the United States of America 109 (2012), E3186–E3195.
87. Ramakrishna, V., Sundarapandiyan, K., Zhao, B., Bylesjo, M., Marsh, H.C., Keler, T., Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab. Journal for Immunotherapy of Cancer, 3, 2015, 37.
88. Ripoll, V.M., Irvine, K.M., Ravasi, T., Sweet, M.J., Hume, D.A., Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. Journal of Immunology 178 (2007), 6557–6566.
89. Ripoll, V.M., Meadows, N.A., Raggatt, L.J., Chang, M.K., Pettit, A.R., Cassady, A.I., Hume, D.A., Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB. Gene 413 (2008), 32–41.
90. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., investigators, K, Pembrolizumab versus ipilimumab in advanced melanoma. The New England Journal of Medicine 372 (2015), 2521–2532.
91. Rose, A.A., Annis, M.G., Dong, Z., Pepin, F., Hallett, M., Park, M., Siegel, P.M., ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties. PLoS One, 5, 2010, e12093.
92. Rose, A.A., Annis, M.G., Frederick, D.T., Biondini, M., Dong, Z., Kwong, L., Siegel, P.M., MAPK pathway inhibitors sensitize BRAF-mutant melanoma to an antibody-drug conjugate targeting GPNMB. Clinical Cancer Research 22 (2016), 6088–6098.
93. Rose, A.A., Grosset, A.A., Dong, Z., Russo, C., Macdonald, P.A., Bertos, N.R., Siegel, P.M., Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clinical Cancer Research 16 (2010), 2147–2156.
94. Rose, A.A., Pepin, F., Russo, C., Abou Khalil, J.E., Hallett, M., Siegel, P.M., Osteoactivin promotes breast cancer metastasis to bone. Molecular Cancer Research 5 (2007), 1001–1014.
95. Roth, M., Barris, D.M., Piperdi, S., Kuo, V., Everts, S., Geller, D., Gorlick, R., Targeting glycoprotein NMB with antibody-drug conjugate, glembatumumab vedotin, for the treatment of osteosarcoma. Pediatric Blood & Cancer 63 (2016), 32–38.
96. Ruan, W.M., Li, Y.L., Nie, G., Zhou, W.X., Zou, X.M., Differential expression of glycoprotein non-metastatic melanoma protein B (GPNMB) involved in trichostatin A-induced apoptosis in gastric cancer. International Journal of Clinical and Experimental Medicine 7 (2014), 4857–4866.
97. Safadi, F.F., Xu, J., Smock, S.L., Rico, M.C., Owen, T.A., Popoff, S.N., Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts. Journal of Cellular Biochemistry 84 (2001), 12–26.
98. Selim, A.A., Abdelmagid, S.M., Kanaan, R.A., Smock, S.L., Owen, T.A., Popoff, S.N., Safadi, F.F., Anti-osteoactivin antibody inhibits osteoblast differentiation and function in vitro. Critical Reviews in Eukaryotic Gene Expression 13 (2003), 265–275.
99. Sheng, M.H., Wergedal, J.E., Mohan, S., Amoui, M., Baylink, D.J., Lau, K.H., Targeted overexpression of osteoactivin in cells of osteoclastic lineage promotes osteoclastic resorption and bone loss in mice. PLoS One, 7, 2012, e35280.
100. Sheng, M.H., Wergedal, J.E., Mohan, S., Lau, K.H., Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity. FEBS Letters 582 (2008), 1451–1458.
101. Shi, F., Duan, S., Cui, J., Yan, X., Li, H., Wang, Y., Xie, X., Induction of matrix metalloproteinase-3 (MMP-3) expression in the microglia by lipopolysaccharide (LPS) via upregulation of glycoprotein nonmetastatic melanoma B (GPNMB) expression. Journal of Molecular Neuroscience 54 (2014), 234–242.
102. Shikano, S., Bonkobara, M., Zukas, P.K., Ariizumi, K., Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans. The Journal of Biological Chemistry 276 (2001), 8125–8134.
103. Smith, M.P., Brunton, H., Rowling, E.J., Ferguson, J., Arozarena, I., Miskolczi, Z., Wellbrock, C., Inhibiting drivers of non-mutational drug tolerance is a salvage strategy for targeted melanoma therapy. Cancer Cell 29 (2016), 270–284.
104. Smith, M.P., Ferguson, J., Arozarena, I., Hayward, R., Marais, R., Chapman, A., Wellbrock, C., Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. Journal of the National Cancer Institute 105 (2013), 33–46.
105. Sobacchi, C., Schulz, A., Coxon, F.P., Villa, A., Helfrich, M.H., Osteopetrosis: Genetics, treatment and new insights into osteoclast function. Nature Reviews. Endocrinology 9 (2013), 522–536.
106. Srinivasan, K., Friedman, B.A., Larson, J.L., Lauffer, B.E., Goldstein, L.D., Appling, L.L., Hansen, D.V., Untangling the brain's neuroinflammatory and neurodegenerative transcriptional responses. Nature Communications, 7, 2016, 11295.
107. Tanaka, M., Homme, M., Yamazaki, Y., Shimizu, R., Takazawa, Y., Nakamura, T., Modeling alveolar soft part sarcoma unveils novel mechanisms of metastasis. Cancer Research 77 (2017), 897–907.
108. Tanaka, H., Shimazawa, M., Kimura, M., Takata, M., Tsuruma, K., Yamada, M., Hara, H., The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis. Scientific Reports, 2, 2012, 573.
109. Thomas, A., Teicher, B.A., Hassan, R., Antibody-drug conjugates for cancer therapy. The Lancet Oncology 17 (2016), e254–e262.
110. Tomihari, M., Chung, J.S., Akiyoshi, H., Cruz, P.D. Jr., Ariizumi, K., DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells. Cancer Research 70 (2010), 5778–5787.
111. Tomihari, M., Hwang, S.H., Chung, J.S., Cruz, P.D. Jr., Ariizumi, K., Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD-dependent fashion. Experimental Dermatology 18 (2009), 586–595.
112. Torres, C., Linares, A., Alejandre, M.J., Palomino-Morales, R., Martin, M., Delgado, J.R., Perales, S., The potential role of the glycoprotein osteoactivin/glycoprotein nonmetastatic melanoma protein B in pancreatic cancer. Pancreas 44 (2015), 302–310.
113. Tse, K.F., Jeffers, M., Pollack, V.A., McCabe, D.A., Shadish, M.L., Khramtsov, N.V., LaRochelle, W.J., CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clinical Cancer Research 12 (2006), 1373–1382.
114. Turque, N., Denhez, F., Martin, P., Planque, N., Bailly, M., Begue, A., Saule, S., Characterization of a new melanocyte-specific gene (QNR-71) expressed in v-myc-transformed quail neuroretina. The EMBO Journal 15 (1996), 3338–3350.
115. + HLA-DR no/low cells are a potential blood marker and therapeutic target for melanoma. The Journal of Investigative Dermatology 134 (2014), 2839–2842.
116. Tyburczy, M.E., Kotulska, K., Pokarowski, P., Mieczkowski, J., Kucharska, J., Grajkowska, W., Kaminska, B., Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. The American Journal of Pathology 176 (2010), 1878–1890.
117. Ugel, S., De Sanctis, F., Mandruzzato, S., Bronte, V., Tumor-induced myeloid deviation: When myeloid-derived suppressor cells meet tumor-associated macrophages. The Journal of Clinical Investigation 125 (2015), 3365–3376.
118. van Lanschot, C.G., Koljenovic, S., Grunhagen, D.J., Verhoef, C., van Akkooi, A.C., Pigmentation in the sentinel node correlates with increased sentinel node tumor burden in melanoma patients. Melanoma Research 24 (2014), 261–266.
119. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr., Kinzler, K.W., Cancer genome landscapes. Science 339 (2013), 1546–1558.
120. Wasmeier, C., Hume, A.N., Bolasco, G., Seabra, M.C., Melanosomes at a glance. Journal of Cell Science 121 (2008), 3995–3999.
121. Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A.J., Chen, Y.A., Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunology Research 4 (2016), 345–353.
122. Wellbrock, C., Arozarena, I., Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. Pigment Cell & Melanoma Research 28 (2015), 390–406.
123. Welsh, S.J., Rizos, H., Scolyer, R.A., Long, G.V., Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?. European Journal of Cancer 62 (2016), 76–85.
124. Weterman, M.A., Ajubi, N., van Dinter, I.M., Degen, W.G., van Muijen, G.N., Ruitter, D.J., Bloemers, H.P., nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. International Journal of Cancer 60 (1995), 73–81.
125. Williams, M.D., Esmaeli, B., Soheili, A., Simantov, R., Gombos, D.S., Bedikian, A.Y., Hwu, P., GPNMB expression in uveal melanoma: A potential for targeted therapy. Melanoma Research 20 (2010), 184–190.
126. Yamaguchi, Y., Hearing, V.J., Physiological factors that regulate skin pigmentation. BioFactors 35 (2009), 193–199.
127. Yardley, D.A., Weaver, R., Melisko, M.E., Saleh, M.N., Arena, F.P., Forero, A., Vahdat, L.T., EMERGE: A randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. Journal of Clinical Oncology 33 (2015), 1609–1619.
128. Zhang, P., Liu, W., Zhu, C., Yuan, X., Li, D., Gu, W., Gao, T., Silencing of GPNMB by siRNA inhibits the formation of melanosomes in melanocytes in a MITF-independent fashion. PLoS One, 7, 2012, e42955.
129. Zhao, Y., Qiao, Z.G., Shan, S.J., Sun, Q.M., Zhang, J.Z., Expression of glycoprotein non-metastatic melanoma protein B in cutaneous malignant and benign lesions: A tissue microarray study. Chinese Medical Journal 125 (2012), 3279–3282.
130. Zigdon, H., Savidor, A., Levin, Y., Meshcheriakova, A., Schiffmann, R., Futerman, A.H., Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease. PLoS One, 10, 2015, e0120194.